Pharmabiz31m
FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025
FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025: Philadelphia Saturday, January 11, 2025, 17:00 Hrs [IST] FORE Bioth ...
Pharmabiz1h
Newron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South Korea
Newron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South Korea: Milan Saturday, January 11, 2025, 16:00 Hrs [IST] ...
Pharmabiz2h
SynCardia Systems gets CNIPA notification granting first patent covering company’s next-generation total artificial heart
SynCardia Systems gets CNIPA notification granting first patent covering company’s next-generation total artificial heart: Tucson, Arizona Saturday, January 11, 2025, 15:00 Hrs ...
Pharmabiz4h
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market: Ireland Saturday, January 11, 2025, 13:30 Hrs [IST] Gaelic Laboratories, a Europea ...
Pharmabiz3h
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology: Ingelheim Saturday, January 11, 2025, 14:00 Hrs [IST] Boehringer Ingelheim and Synaf ...
Pharmabiz4h
Seven research leaders awarded prestigious NIHR award
The NIHR has announced the latest outstanding researchers to become NIHR Research Professors. They will play a key role in undertaking professorial-level research that has a positive impact on the ...
Pharmabiz5h
US FDA grants priority review status to Johnson & Johnson’s nipocalimab BLA to treat generalized myasthenia gravis
Spring House, Pennsylvania Saturday, January 11, 2025, 12:00 Hrs [IST] ...
Pharmabiz7h
Astellas Pharma announces US FDA confirms Class 1 resubmission of the sNDA for Izervay for geographic atrophy
Astellas Pharma announces US FDA confirms Class 1 resubmission of the sNDA for Izervay for geographic atrophy: Tokyo Saturday, January 11, 2025, 10:00 Hrs [IST] Astellas Pharma In ...
Pharmabiz3d
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease
JCR Pharmaceuticals Co., Ltd., a global specialty pharmaceuticals company, and Modalis Therapeutics Corporation, a forerunner in the field of epigenetic medicine, announced that they have validated ...
Pharmabiz3d
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection
Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, announced that it has ...
Pharmabiz4d
Biotech Showcase 2025 is set to convene in San Francisco for Biotech Investor Conference
Biotech Showcase 2025, an exciting and content-packed programme it dives deep into the future of biotechnology and healthcare innovation, will once again serve as the premier destination for global ...
Pharmabiz4d
ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians
ResMed, the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, has launched AirSense 11 in India. The company’s next-generation Continuous Positive ...